FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100173894> ?p ?o ?g. }

• W2100173894 endingPage "79" @default.
• W2100173894 startingPage "52" @default.
• W2100173894 abstract "Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vascularization and, in time, acquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastatic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, such as the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic drugs, as well as the development of multidrug resistance, support the need to find new effective targeted treatments based on the changes in the molecular biology of the tumor cells. These novel targeted therapies, of increasing interest as evidenced by FDA-approved targeted cancer drugs in recent years, block biologic transduction pathways and/or specific cancer proteins to induce the death of cancer cells by means of apoptosis and stimulation of the immune system, or specifically deliver chemotherapeutic agents to cancer cells, minimizing the undesirable side effects. Although targeted therapies can be achieved directly by altering specific cell signaling by means of monoclonal antibodies or small molecules inhibitors, this review focuses on indirect targeted approaches that mainly deliver chemotherapeutic agents to molecular targets overexpressed on the surface of tumor cells. In particular, we offer a detailed description of different cytotoxic drug carriers, such as liposomes, carbon nanotubes, dendrimers, polymeric micelles, polymeric conjugates and polymeric nanoparticles, in passive and active targeted cancer therapy, by enhancing the permeability and retention or by the functionalization of the surface of the carriers, respectively, emphasizing those that have received FDA approval or are part of the most important clinical studies up to date. These drug carriers not only transport the chemotherapeutic agents to tumors, avoiding normal tissues and reducing toxicity in the rest of the body, but also protect cytotoxic drugs from degradation, increase the half-life, payload and solubility of cytotoxic agents and reduce renal clearance. Despite the many advantages of all the anticancer drug carriers analyzed, only a few of them have reached the FDA approval, in particular, two polymer-protein conjugates, five liposomal formulations and one polymeric nanoparticle are available in the market, in contrast to the sixteen FDA approval of monoclonal antibodies. However, there are numerous clinical trials in progress of polymer-protein and polymer-drug conjugates, liposomal formulations, including immunoliposomes, polymeric micelles and polymeric nanoparticles. Regarding carbon nanotubes or dendrimers, there are no FDA approvals or clinical trials in process up to date due to their unresolved toxicity. Moreover, we analyze in detail the more promising and advanced preclinical studies of the particular case of polymeric nanoparticles as carriers of different cytotoxic agents to active and passive tumor targeting published in the last 5 years, since they have a huge potential in cancer therapy, being one of the most widely studied nano-platforms in this field in the last years. The interest that these formulations have recently achieved is stressed by the fact that 90% of the papers based on cancer therapeutics with polymeric nanoparticles have been published in the last 6 years (PubMed search)." @default.
• W2100173894 created "2016-06-24" @default.
• W2100173894 creator A5019101850 @default.
• W2100173894 creator A5055108378 @default.
• W2100173894 date "2015-06-01" @default.
• W2100173894 modified "2023-10-18" @default.
• W2100173894 title "Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy" @default.
• W2100173894 cites W140161251 @default.
• W2100173894 cites W1494188064 @default.
• W2100173894 cites W1499573758 @default.
• W2100173894 cites W1512026049 @default.
• W2100173894 cites W1534849470 @default.
• W2100173894 cites W1579199344 @default.
• W2100173894 cites W1692977678 @default.
• W2100173894 cites W176983039 @default.
• W2100173894 cites W1918322381 @default.
• W2100173894 cites W1963515569 @default.
• W2100173894 cites W1963527493 @default.
• W2100173894 cites W1963662302 @default.
• W2100173894 cites W1964185052 @default.
• W2100173894 cites W1964270561 @default.
• W2100173894 cites W1965063429 @default.
• W2100173894 cites W1965800158 @default.
• W2100173894 cites W1965995589 @default.
• W2100173894 cites W1966095507 @default.
• W2100173894 cites W1966118388 @default.
• W2100173894 cites W1966312615 @default.
• W2100173894 cites W1966692264 @default.
• W2100173894 cites W1967637067 @default.
• W2100173894 cites W1967708299 @default.
• W2100173894 cites W1968583232 @default.
• W2100173894 cites W1968627984 @default.
• W2100173894 cites W1969192656 @default.
• W2100173894 cites W1970720922 @default.
• W2100173894 cites W1972521011 @default.
• W2100173894 cites W1975298683 @default.
• W2100173894 cites W1975341277 @default.
• W2100173894 cites W1975408440 @default.
• W2100173894 cites W1976041621 @default.
• W2100173894 cites W1976060898 @default.
• W2100173894 cites W1976932813 @default.
• W2100173894 cites W1977202079 @default.
• W2100173894 cites W1977528153 @default.
• W2100173894 cites W1978183755 @default.
• W2100173894 cites W1978640331 @default.
• W2100173894 cites W1979389654 @default.
• W2100173894 cites W1979716619 @default.
• W2100173894 cites W1981116681 @default.
• W2100173894 cites W1981700062 @default.
• W2100173894 cites W1981745506 @default.
• W2100173894 cites W1981825595 @default.
• W2100173894 cites W1981853312 @default.
• W2100173894 cites W1982117677 @default.
• W2100173894 cites W1982267988 @default.
• W2100173894 cites W1982902233 @default.
• W2100173894 cites W1984239269 @default.
• W2100173894 cites W1984697909 @default.
• W2100173894 cites W1985052696 @default.
• W2100173894 cites W1986006871 @default.
• W2100173894 cites W1987782083 @default.
• W2100173894 cites W1988376711 @default.
• W2100173894 cites W1988505882 @default.
• W2100173894 cites W1989353157 @default.
• W2100173894 cites W1989773773 @default.
• W2100173894 cites W1989973877 @default.
• W2100173894 cites W1990455420 @default.
• W2100173894 cites W1990827779 @default.
• W2100173894 cites W1990869510 @default.
• W2100173894 cites W1991154912 @default.
• W2100173894 cites W1991195879 @default.
• W2100173894 cites W1991462498 @default.
• W2100173894 cites W1991716060 @default.
• W2100173894 cites W1992431969 @default.
• W2100173894 cites W1992904959 @default.
• W2100173894 cites W1992994818 @default.
• W2100173894 cites W1993078113 @default.
• W2100173894 cites W1995310779 @default.
• W2100173894 cites W1995637639 @default.
• W2100173894 cites W1995650484 @default.
• W2100173894 cites W1995980440 @default.
• W2100173894 cites W1996186923 @default.
• W2100173894 cites W1996198321 @default.
• W2100173894 cites W1996549325 @default.
• W2100173894 cites W1996998905 @default.
• W2100173894 cites W1997581567 @default.
• W2100173894 cites W1999204999 @default.
• W2100173894 cites W1999312756 @default.
• W2100173894 cites W1999607053 @default.
• W2100173894 cites W1999705499 @default.
• W2100173894 cites W2000205238 @default.
• W2100173894 cites W2001018320 @default.
• W2100173894 cites W2001629813 @default.
• W2100173894 cites W2001753204 @default.
• W2100173894 cites W2001823241 @default.
• W2100173894 cites W2002090994 @default.
• W2100173894 cites W2002815709 @default.
• W2100173894 cites W2003381115 @default.
• W2100173894 cites W2003495186 @default.

• next